Colorectal Cancer Medical Services in China

Colorectal cancer (CRC) is a malignant neoplasm arising from the epithelial lining of the colon or rectum, typically developing from adenomatous polyps through the adenoma-carcinoma sequence. Risk factors include age (>50 years), familial history (e.g., Lynch syndrome, familial adenomatous polyposis), inflammatory bowel disease, obesity, smoking, and diets high in red or processed meats. Clinical presentation may include hematochezia, change in bowel habits, abdominal pain, iron-deficiency anemia, or unexplained weight loss. Diagnosis relies on colonoscopy with biopsy, supplemented by cross-sectional imaging (CT/MRI), PET-CT for staging, and molecular profiling (e.g., KRAS/NRAS/BRAF mutations, MSI status) to guide targeted therapy. Treatment is multimodal: surgical resection remains curative for localized disease; adjuvant chemotherapy (e.g., FOLFOX/CAPOX) is standard for stage III and high-risk stage II; neoadjuvant chemoradiation is employed for locally advanced rectal cancer; and biologics (anti-EGFR or anti-VEGF agents) plus immunotherapy (for MSI-H/dMMR tumors) are integral in metastatic settings.

China offers compelling advantages for international patients seeking CRC care. The country hosts nationally accredited oncology centers—many designated as National Clinical Research Bases—with multidisciplinary tumor boards led by surgeons, medical oncologists, radiation oncologists, and pathologists experienced in complex CRC cases. Advanced technologies—including robotic-assisted laparoscopic surgery (da Vinci Xi), intensity-modulated radiotherapy (IMRT), and next-generation sequencing platforms—are widely deployed in Tier-1 hospitals. Five-year overall survival rates for stage II–III CRC exceed 75% in leading institutions, supported by robust clinical trial participation and real-world outcome data published in journals such as *The Lancet Oncology* and *JAMA Oncology*. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising evidence-based protocols or regulatory compliance (NMPA-approved therapeutics and devices).

As a dedicated medical tourism agency, we facilitate seamless access to these high-quality services for international patients. We coordinate hospital appointments with top-tier CRC specialists, provide itemized, transparent pricing in advance, assist with visa documentation, arrange accommodation and interpreter services, and offer continuous case management—from pre-travel consultation through post-treatment follow-up. Our network includes JCI-accredited hospitals and centers recognized by the Chinese Society of Clinical Oncology (CSCO), ensuring adherence to internationally aligned standards of care.

Treatment Options & Itemized Cost Breakdown: Colorectal Cancer (Oncology Department)

Non-Surgical / Medical Therapy

*Indicated for Stage II–IV, unresectable disease, adjuvant/neoadjuvant settings, or palliation.*

• •Chemotherapy (FOLFOX/FOLFIRI):

- *Cost (per cycle)*: ¥8,500–¥12,000 → $1,180–$1,670 - Oxaliplatin (generic): ¥3,200 - 5-FU + leucovorin infusion: ¥2,100 - Supportive antiemetics (palonosetron + dexamethasone): ¥480 - Day-care nursing & IV administration: ¥1,900

• •Targeted Therapy (anti-EGFR/VEGF):

- *Cost (per dose)*: - Cetuximab (250 mg/m²): ¥14,200 → $1,975 - Bevacizumab (7.5 mg/kg): ¥5,600 → $780

• •Immunotherapy (PD-1 inhibitors):

- *Cost (per 200 mg dose)*: - Sintilimab: ¥6,800 → $945 - Toripalimab: ¥5,900 → $820

• •Diagnostic/Lab Fees (per cycle):

- CBC, LFTs, creatinine: ¥280 → $39 - RAS/BRAF testing (NGS panel): ¥2,400 → $334

Surgical / Procedural Options

*Indicated for localized (Stage I–III) or oligometastatic (liver/lung) disease.*

• •Laparoscopic Colectomy (Right/Left/Sigmoid):

- *Cost*: ¥32,000–¥45,000 → $4,450–$6,260 - Surgeon/anesthesia fees: ¥14,500 - Laparoscopic instruments & disposables: ¥9,800 - ICU monitoring (1 day avg): ¥3,200

• •Robotic-Assisted Resection:

- *Cost*: ¥58,000–¥72,000 → $8,070–$10,020

• •Preoperative Workup (mandatory):

- Pelvic MRI (rectal cancer): ¥1,800 → $250 - Cardiopulmonary evaluation (ECG, echo, PFTs if >65 yrs): ¥1,350 → $188

Special/Complex Scenarios

• •Liver Metastasectomy (open/robotic): ¥65,000–¥89,000 → $9,040–$12,380
• •Neoadjuvant Chemoradiation (rectal): 25 fractions + capecitabine: ¥24,000 → $3,340
• •Palliative Stent Placement (obstructing tumor): ¥15,500 → $2,155

Quick Selection Guide

• •<60 yrs, Stage III, fit: Laparoscopic colectomy + adjuvant FOLFOX ($4,450–$6,260 + $1,180/cycle × 12)
• •>75 yrs, comorbidities, Stage II: Single-agent capecitabine (¥3,800/cycle → $530) + surveillance
• •MSI-H Stage IV, limited mets: Immunotherapy first-line ($945/dose q3w) — avoids chemo toxicity
• •Budget-constrained (<$5,000 total): Palliative stent + best supportive care ($2,155 + $300/month)
• •Locally advanced rectal: Neoadjuvant chemoradiation → surgery ($3,340 + $4,450+) — improves sphincter preservation